Iridian Asset Management’s TG Therapeutics TGTX Stock Holding History

Iridian Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.52M	Sell	27,689 -47,600	-63%	-$1.95M	0.52%	31
2026 Q1	$2.5M	Hold	75,289	–	–	1.01%	27
2025 Q4	$2.24M	Hold	75,289	–	–	0.83%	29
2025 Q3	$2.72M	Buy	75,289 +27,757	+58%	+$914K	1.07%	28
2025 Q2	$1.71M	Hold	47,532	–	–	0.59%	34
2025 Q1	$1.87M	Hold	47,532	–	–	0.59%	35
2024 Q4	$1.43M	Hold	47,532	–	–	0.38%	37
2024 Q3	$1.11M	Buy	47,532 +8,175	+21%	+$179K	0.24%	39
2024 Q2	$700K	Buy	+39,357	New	+$628K	0.16%	45

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Iridian Asset Management's TGTX Position: Q2 2026 in Review

Iridian Asset Management reduced its TG Therapeutics (TGTX) stake by 63% in Q2 2026, selling an estimated $1.95M and leaving 27,689 shares worth $1.52M. The position accounts for 0.52% of the portfolio, ranked #31.

Iridian Asset Management first reported a position in TGTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.72M in Q3 2025. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Iridian Asset Management held 27,689 shares of TG Therapeutics worth $1.52M as of Q2 2026.
Iridian Asset Management sold 47,600 TG Therapeutics shares in Q2 2026, an estimated $1.95M.
TG Therapeutics made up 0.52% of Iridian Asset Management's portfolio in Q2 2026, its #31 holding.
Iridian Asset Management first reported a position in TG Therapeutics in Q2 2024 and has held it in 9 quarters since.
Iridian Asset Management's TG Therapeutics position peaked at $2.72M in Q3 2025.
427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Iridian Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.